- 1 Genetic Association and Transferability for Urinary Albumin-Creatinine Ratio as a
- 2 Marker of Kidney Disease in four Sub-Saharan African Populations and non-continental
- 3 **Individuals of African Ancestry**
- Jean-Tristan Brandenburg (PhD)<sup>1,2</sup>, Wenlong Carl Chen (PhD)<sup>1,2,3</sup>, Palwende Romuald Boua 5
- (PhD)<sup>1,4</sup>, Melanie Ann Govender (MSc)<sup>1,5</sup>, Godfred Agongo (PhD)<sup>6,7</sup>, Lisa K. Micklesfield 6
- (PhD)<sup>8</sup>, Hermann Sorgho (PhD)<sup>4</sup>, Stephen Tollman (MD, PhD)<sup>9</sup>, Gershim Asiki (MD, 7
- PhD)<sup>10,11</sup>, Felistas Mashinya (PhD)<sup>12</sup>, Scott Hazelhurst (PhD)<sup>1,13</sup>, Andrew P Morris (PhD)<sup>14</sup>, 8
- June Fabian (MD)<sup>15\*</sup>, Michèle Ramsay (PhD)<sup>1,5\*</sup> as members of AWI-Gen and the H3Africa 9
- 10 Consortium

11

- <sup>1</sup> Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University 12
- of the Witwatersrand, Johannesburg, South Africa 13
- 14 <sup>2</sup> Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University of
- 15 the Witwatersrand, Johannesburg, South Africa
- <sup>3</sup> National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa 16
- 17 <sup>4</sup> Clinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Burkina
- 18 Faso

39

41

- <sup>5</sup> Division of Human Genetics, National Health Laboratory Service and School of Pathology, 19
- 20 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- <sup>6</sup> Navrongo Health Research Centre, Navrongo, Ghana 21
- <sup>7</sup> Department of Biochemistry and Forensic Sciences, School of Chemical and Biochemical 22
- 23 Sciences, C. K. Tedam University of Technology and Applied Sciences, Navrongo, Ghana
- 24 <sup>8</sup> SAMRC/Wits Developmental Pathways for Health Research Unit, Faculty of Health
- Sciences, University of the Witwatersrand, Johannesburg, South Africa 25
- 26 <sup>9</sup> Medical Research Council/Wits University Rural Public Health and Health Transitions
- 27 Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of
- the Witwatersrand, Johannesburg, South Africa 28
- <sup>10</sup> African Population and Health Research Center, Nairobi, Kenya. 29
- <sup>11</sup> Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden 30
- <sup>12</sup> Department of Pathology and Medical Sciences, School of Health Care Sciences, Faculty of 31
- Health Sciences, University of Limpopo, Polokwane, South Africa 32
- 33 <sup>13</sup> School of Electrical and Information Engineering, University of the Witwatersrand,
- Johannesburg, South Africa 34
- 35 <sup>14</sup> Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research,
- 36 The University of Manchester, Manchester, UK
- 37 <sup>15</sup> Wits Donald Gordon Medical Centre, School of Clinical Medicine, Faculty of Health
- 38 Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 40 \*These authors contributed equally to this work and share senior authorship
- Corresponding authors: Dr Jean-Tristan Brandenburg and Prof Michèle Ramsay, Sydney 42
- Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Witwatersrand, 9 Jubilee Road, Parktown, Johannesburg, South Africa 43
- 44

45 Tel: +27 11 717 6635

- 46 E-mail: jean-tristan.brandenburg@wits.ac.za and michele.ramsay@wits.ac.za
- 48 Support: National Institutes of Health (NIH) H3Africa AWI-Gen Collaborative Centre
- 49 (U54HG006938).

47

50

52

53

56

57

Running title: GWAS for UACR in African-ancestry populations

# Keywords (6)

- 54 Chronic kidney disease (CKD), genome-wide association study (GWAS), urinary albumin-
- creatinine ratio (UACR), African diversity, polygenic risk score

# Abstract (251 words)

- 58 Background: Genome-wide association studies (GWAS) have predominantly focused on
- 59 populations of European and Asian ancestry, limiting our understanding of genetic factors
- 60 influencing kidney disease in Sub-Saharan African (SSA) populations. This study presents the
- 61 largest GWAS for urinary albumin-to-creatinine ratio (UACR) in SSA individuals, including
- 8,970 participants living in different African regions and an additional 9,705 non-resident
- 63 individuals of African ancestry from the UK Biobank and African American cohorts.
- 64 Methods: Urine biomarkers and genotype data were obtained from two SSA cohorts (AWI-
- 65 Gen and ARK), and two non-resident African-ancestry studies (UK Biobank and CKD-Gen
- 66 Consortium). Association testing and meta-analyses were conducted, with subsequent fine-
- 67 mapping, conditional analyses, and replication studies. Polygenic scores (PGS) were assessed
- 68 for transferability across populations.
- Results: Two genome-wide significant (P<5x10<sup>-8</sup>) UACR-associated loci were identified, one
- 70 in the BMP6 region on chromosome 6, in the meta-analysis of resident African individuals,
- and another in the *HBB* region on chromosome 11 in the meta-analysis of non-resident SSA
- 72 individuals, as well as the combined meta-analysis of all studies. Replication of previous
- 73 significant results confirmed associations in known UACR-associated regions, including
- 74 THB53, GATM, and ARL15. PGS estimated using previous studies from European ancestry,
- African ancestry, and multi-ancestry cohorts exhibited limited transferability of PGS across
- populations, with less than 1% of observed variance explained.
- 77 **Conclusion**: This study contributes novel insights into the genetic architecture of kidney
- disease in SSA populations, emphasizing the need for conducting genetic research in diverse

- 79 cohorts. The identified loci provide a foundation for future investigations into the genetic
- 80 susceptibility to chronic kidney disease in underrepresented African populations Additionally,
- 81 there is a need to develop integrated scores using multi-omics data and risk factors specific to
- 82 the African context to improve the accuracy of predicting disease outcomes.

## Introduction

83

84

- 85 Chronic kidney disease (CKD) is a leading risk factor for years of life lost and premature
- 86 mortality, with a 41.5% relative increase in mortality worldwide from 1990 to 2017 (GBD
- 87 Chronic Kidney Disease Collaboration et al., 2020; Kovesdy, 2022). The estimated global
- prevalence of CKD is 9.1% and while predicted to be higher in Sub-Saharan Africa (SSA), the
- 89 true prevalence and associated risk factors remain understudied (Kaze et al., 2018; GBD
- 90 Chronic Kidney Disease Collaboration et al., 2020). The Africa Wits-INDEPTH partnership
- 91 for Genomic Studies (AWI-Gen) cohort, which included ~12,000 participants from four SSA
- countries in West, East, and Southern Africa, reported overall CKD prevalence as 10.7% (95%)
- 93 confidence interval [CI]: 9.9-11.7), with notable geographic regional differences. The most
- 94 important risk factors for CKD in SSA were older age, female sex, diabetes, hypertension, and
- human immunodeficiency virus (HIV) infection (George et al., 2019).
- 96 Over the past decade, genome-wide association studies (GWAS) have identified numerous
- 97 genetic loci associated with kidney function disease, namely, estimated glomerular filtration
- rate [eGFR], serum creatinine, and urine albumin-creatinine ratio [UACR] (Böger et al., 2011;
- 99 Pattaro et al., 2012, 2016; Teumer et al., 2016, 2019; Hellwege et al., 2019; Tin and Köttgen,
- 100 2020). The majority of the GWAS for kidney function and disease have examined associations
- with eGFR, while UACR, as a measure for albuminuria, has been investigated less often
- 102 (Mahajan et al., 2016; Pattaro et al., 2016; Gorski et al., 2017; Haas et al., 2018; Teumer et al.,
- 2019; Wuttke et al., 2019; Zanetti et al., 2019). A recent GWAS in 564,257 individuals of
- multi-ancestry origins identified 68 associated risk loci for UACR were identified and proposed
- priority list of genes to explore as targets for the treatment of albuminuria (Teumer et al., 2019).
- While the majority of kidney disease-associated risk loci have been identified in studies on
- participants of European and East Asian ancestry, and the African diaspora (Lee et al., 2018),
- 108 few have focused on participants living in SSA (Böger et al., 2011; Pattaro et al., 2012; Lin et
- al., 2019; Morris et al., 2019). Recently, in a study of genetic associations of eGFR in a
- Ugandan population-based cohort, (Fatumo et al., 2020) replicated the association between
- eGFR and the *GATM* locus .

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

Replication and transferability of GWAS signals across populations of different ancestries, and specifically with African ancestry populations, tend to be poor despite regional replication often identifying shared associated genomic regions (Pattaro et al., 2012). This may be due to differences in linkage disequilibrium (LD) with the causal variant, allele frequency differences between the populations, underlying population structure, and variabilities in environmental exposures. African populations, with their great genetic diversity and deep evolutionary roots, represent an opportunity for genetic discovery to identify and fine-map disease-associated risk variants (Gomez et al., 2014; Pereira et al., 2021). Polygenic scores (PGS) are used to quantify and stratify populations according to genetic risk. A PGS based on 63 eGFR-associated alleles showed significant association with kidney disease-related phenotypes, such as chronic kidney failure and hypertensive kidney disease in the Million Veteran Study (US) on 192,868 white and non-Hispanic individuals (Hellwege et al., 2019). A PGS based on 64 urine albumin-to-creatinine ratio (UACR) associated alleles was significantly associated with CKD (Teumer et al., 2019). Further analysis revealed positive associations of the PGS with an increased risk of HT and diabetes. However, PGS often translate poorly across different ancestries (Martin et al., 2017; Kamiza et al., 2022; Kachuri et al., 2023). Since most published GWAS for kidney disease and kidney function markers are based on European ancestry populations, the predictive accuracy of models developed from these studies is expected to be significantly diminished for African populations (Adam et al., 2022; Choudhury et al., 2022; Kamiza et al., 2023; Majara et al., 2023). In this study, we present a GWAS for UACR conducted within resident Sub-Saharan African individuals. This population cross-sectional study includes a cohort of 8,970 individuals from four SSA countries from the AWI-Gen study (Ali et al., 2018), the African Research on Kidney Disease (ARK) study (Kalyesubula et al., 2020), with 9,705 individuals of African-ancestry from the UK Biobank (UKB) and African American participants from the CKD-Gen Consortium (Teumer et al., 2019). The primary objectives are to: (1) identify genetic loci associated with UACR as a marker of kidney disease in individuals from SSA and of African ancestry; (2) explore the replication of findings identified in previous GWAS; (3) perform analysis and comparison of PGS derived from non-African and multi-ancestry population studies and evaluate their transferability to African populations.

# **Participants and Methods**

**Study participants** 

145 Africa Wits-INDEPTH Partnership for Genomic Research (AWI-Gen)

The study participants are a subset of the population cross-sectional AWI-Gen study (Ramsay et al., 2016; Ali et al., 2018). The study recruited adults primarily between the ages of 40 and 80 years from six SSA study sites in West Africa (Nanoro, Burkina Faso and Navrongo, Ghana), East Africa (Nairobi, Kenya) and in South Africa (Bushbuckridge - hereinafter referred to as Agincourt Mpumalanga Province, Dikgale, Limpopo Province; and Soweto, Gauteng Province). All participants were of self-identified black ethnicity. Data collection was described in detail previously (Ali et al., 2018; George et al., 2019). Detailed demographic data, health-related questionnaire data, and anthropometric measurements were collected. Peripheral blood samples and urine samples were collected for biomarker assays (the relevant assays are described below). DNA was extracted from peripheral blood-derived buffy coat samples and used for genotyping. Urine microalbumin was measured using a colorimetric method on the Cobas© 6000/c501 analyzer, and urine creatinine was measured by the modified Jaffe method(Craik et al., 2023). This study was approved by the Human Research Ethics Committee (Medical), University of the Witwatersrand, South Africa (M121029, M170880)

and the ethics committees of all participating institutions. All participants provided written

informed consent following community engagement and individual consenting processes.

162 African Research on Kidney Disease (ARK)

The African Research Kidney Disease (ARK) study is a well characterised population-based cohort study of 2021 adults (20–80 years) of self-identified black ethnicity from Agincourt, (Mpumalanga, South Africa) with demographic data, health-related questionnaire data, and anthropometric measurements collected at enrolment (Fabian et al., 2022). Blood and urine were collected for biomarker assays (the relevant assays are described below). DNA was extracted from buffy coat samples and used for genotyping. Urine microalbumin was measured using a colorimetric method on the Cobas© 6000/c501 analyzer, and urine creatinine was measured by the modified Jaffe method(Craik et al., 2023). This study was approved by the Human Research Ethics Committee (Medical), University of the Witwatersrand, South Africa (M160939). All participants provided written informed consent following community

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

engagement and individual consenting processes. The geographical area of recruitment overlaps with the Agincourt sub-cohort of AWI-Gen but there is no overlap in participants. UK Biobank (UKB) Individuals of self-reported Caribbean and African ancestry from the UKB were identified for this study. Of this subset of UKB individuals, those with both genotyping and UACR data were retained for the analysis. UACR was derived using urinary levels of albumin and creatinine. In the UKB, albumin was measured using the immuno-turbidimetric analysis method (Randox Biosciences, UK) while creatinine was measured using the enzymatic analysis method (Beckman Coulter, UK) (Casanova et al., 2019). Phenotype generation and harmonization UACR was calculated for AWI-Gen and ARK studies using urinary levels of albumin and creatinine as previously described (George et al., 2019; Fabian et al., 2022). Participants with missing values for albumin and creatinine were excluded from this study. We applied filtering criteria similar to those employed by the CKD-Gen consortium (Köttgen and Pattaro, 2020). In cases where the values for urine albumin and urine creatinine fell outside the upper and lower limits of detection, the values were replaced with the respective upper and lower limits: for urine creatinine, the range was 3 to 400 mmol/L and for urine albumin, the range was 3.75 to 475 mg/L for AWI-Gen and ARK. For the UKB dataset, the upper limit was 6.7 mg/L for urine albumin. Albuminuria was defined as UACR >3.0mg/mmol. Genotyping AWI-Gen and ARK Genomic DNA was genotyped using the H3Africa custom genotyping array. The H3Africa custom array was designed as an African-common-variant-enriched GWAS array (https://www.h3abionet.org/h3africa-chip) (Illumina) with ~2.3 million single nucleotide polymorphisms (SNPs). UK-Biobank Genotyping was performed by Affymetrix on two closely related purpose-designed arrays. ~50,000 participants were genotyped using the UK BiLEVE Axiom array (Resource 149600) and the remaining ~450,000 were genotyped using the UK Biobank Axiom array (Resource 149601). The dataset is a combination of results from both arrays. A total of 805,426 markers

204

205

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

were released in the genotype data. We extracted individuals with self-reported (Data-Field in dataset 21000) African Ancestry split between African (UKB-African) and Caribbean origins (UKB-Caribbean) from the raw dataset (Casanova et al., 2019). 206 Quality control For each dataset, AWI-Gen (Choudhury et al., 2022), ARK and UKB, the following preimputation quality control (QC) steps were applied: removal of non-autosomal and mitochondrial SNPs; SNPs with genotype missingness greater than 0.05; minor allele frequency (MAF) less than 0.01; and Hardy-Weinberg equilibrium (HWE) P-value less than 0.0001. Individuals were excluded if they had more than 5% overall genotype missingness; heterozygosity lower than 0.150 and higher than 0.343; and discordant genotype and phenotype sex information. We used the GWAS QC workflow of the H3Africa Consortium Pan-African **Bioinformatics** Network perform data QC (H3ABioNet H3AGWAS) (https://github.com/h3abionet/h3agwas) (Baichoo et al., 2018; Brandenburg et al., 2022a). In our final QC step, we identified and excluded outliers, admixed and related individuals using PCASmart, a feature of the EIGENSOFT software (Price et al., 2006), Admixture software (Alexander et al., 2009) using AGV (Gurdasani et al., 2015) and 1000 Genomes Project data (Auton et al., 2015) and PLINK (Version 1.9) (Purcell et al., 2007; Chang et al., 2015). More detail on filter parameters for each software can be found in **Supplementary Table 1**. *Imputation* Genotype imputation was performed on each dataset separately (AWI-Gen, ARK, and UKB) using the Sanger Imputation Server with the African Genome Resources reference panel (https://www.sanger.ac.uk/tool/sanger-imputation-service/). EAGLE2 was used for prephasing and the PBWT algorithm was used for imputation (Loh et al., 2016). After imputation, poorly imputed SNPs with info scores less than 0.3 and with a HWE P-value less than 1x10<sup>-04</sup> were removed. The genomic positions were mapped to GRCh37p11. Phenotype transformation for association testing For AWI-Gen, ARK, and UKB datasets, UACR was transformed on the logarithm scale. Linear regression of variables was performed with covariates in R (Version 3.6): ln(UACR) ~age + sex + genetic principal components (PCs) 1-5. Residuals were extracted and transformed using Rank-Based Inverse Normal Transformation to ensure the normal distribution of residuals (Casanova et al., 2019). PCs were calculated using a sub-set of LD pruned pre-imputed SNPs

in PLINK (Version 1.9) (Purcell et al., 2007; Chang et al., 2015). The sub-set was derived by

LD pruning using PLINK (Version 1.9) (Purcell et al., 2007; Chang et al., 2015) with an LD

236 (r<sup>2</sup>) threshold of 0.2 with windows of 50 kb and 10 kb for step size.

Association testing

235

237

- 238 Mixed model association testing was performed with imputed genotype probabilities using
- 239 GEMMA (Version 0.98.1) (Zhou and Stephens, 2012). GEMMA uses a relatedness matrix to
- account for genetic structure and relatedness between individuals. The relatedness matrix was
- built with a sub-set of pre-imputed SNPs described above.
- 242 Mixed model association testing was performed independently on each dataset. A total of nine
- 243 datasets were tested. The datasets were defined as follows: six datasets for AWI-Gen: AWI-
- 244 Agincourt, AWI- Dikgale, AWI-Nanoro, AWI-Nairobi, AWI-Navrongo and AWI-Soweto;
- one dataset for ARK: ARK-Agincourt; and two datasets for UK Biobank: UKB-Caribbean and
- 246 UKB-African. For each dataset, Quantile-to-quantile plots (QQ-plots) were generated, and
- 247 inflation factors were calculated using SNPs with MAF>0.01 to verify that the association
- signals were not inflated due to unaccounted population sub-structure. The genome-wide
- significance level for novel discovery was considered at P<5x10<sup>-08</sup>.
- 250 CKD-Gen
- We used previously published meta-analysis summary statistics from the CKD-Gen
- 252 Consortium. The CKD-Gen Consortium datasets consist of three meta-analysis summary
- statistics: 1) CKD-Gen European ancestry individuals (CKD-Gen-EA); 2) CKD-Gen African
- American ancestry individuals (CKD-Gen-AA); and 3) CKD-Gen Multi-ancestry individuals
- 255 (CKD-Gen-MA) which include individuals from CKD-Gen-EA and CKD-Gen-AA (Teumer
- et al., 2019). The CKD-Gen Consortium meta-analysis summary statistics were retrieved from
- 257 http://ckdgen.imbi.uni-freiburg.de/.
- 258 Briefly, CKD-Gen-AA is a meta-analysis based on 7 studies with African American
- 259 participants. For each study, genotyping was performed using genome-wide arrays followed
- by application of study-specific quality filters prior to phasing, imputation, and association
- analysis software (description can be found in **Supplementary Table 1 and 2** from (Teumer
- et al., 2019)). Meta-analysis was performed using fixed effects inverse-variance weighted
- 263 meta-analysis of the study-specific GWAS result files with imputation quality (IO) score > 0.6
- and MAC > 10, effective sample size  $\ge$  100, and a beta < 10, using METAL (for more details
- 265 see (Teumer et al., 2019)).

**Meta-analysis** 

266

Fixed-effect meta-analyses were conducted using the METASOFT software (Han and Eskin, 267 268 2011). The first meta-analysis (Meta<sub>SSA</sub>) used the GWAS summary statistics generated from 269 individual-level data from resident SSA populations. This included AWI-Agincourt, AWI-270 Dikgale, AWI-Nanoro, AWI-Nairobi, AWI-Navrongo, AWI-Soweto and ARK-Agincourt. 271 The second meta-analysis (Meta<sub>NONRES</sub>) included data from individuals of African ancestry 272 who are not residing in SSA. We used the GWAS summary statistics generated from 273 individual-level data from the UK-Biobank (UKB-African and UKB-Caribbean) and CKD-274 Gen African American sub-set (CKD-Gen-AA). The third meta-analysis (Meta<sub>ALL</sub>) consisted 275 of a meta-analysis that pooled the summary statistics of all studies from AWI-Agincourt, AWI-276 Dikgale, AWI-Nanoro, AWI-Nairobi, AWI-Navrongo, AWI-Soweto, ARK-Agincourt, UKB-277 African, UKB-Caribbean and CKD-Gen-AA. Figure 1 outlines the meta-analysis workflow. 278 As a secondary analysis, role of heterogeneity had been investigated between cohorts from 279 different regions of origin by performing separate meta-analyses for residents of Southern 280 African (AWI-Agincourt, AWI-Dikgale, AWI-Soweto, and ARK-Agincourt) and residents of 281 West Africa (AWI-Nanoro, AWI-Navrongo). Random-effects model from METASOFT (Han 282 and Eskin, 2011) take account for potential heterogeneity between study, we performed Meta RE using all dataset (Meta<sub>ALL</sub><sup>RE</sup>) (Borenstein et al., 2010; Adriani Nikolakopoulou et al., 2014). 283 The genome-wide significance level for novel discovery was considered at  $P<5x10^{-08}$ . 284

### Post association analysis

287 Plotting

285

286

- QQ-plots and Manhattan plots were generated using the FastMan library (Paria et al., 2022)
- 289 (available at https://github.com/kaustubhad/fastman) and the Hudson library (available at
- 290 https://github.com/anastasia-lucas/hudson). These visualizations were created using SNPs with
- a MAF threshold of 0.01 or more. For regional plots, we utilized the standalone version of the
- 292 LocusZoom software (Pruim et al., 2010).
- 293 Genetic LD reference
- 294 For the estimation of the LD reference panel for conditional and joint (COJO) analysis,
- clumping, and fine-mapping, three LD reference panels were constructed using genotype data
- from the appropriate datasets. For resident SSA dataset comparisons, the LD reference panel

297 (LD<sub>SSA</sub>) was constructed using AWI-Gen and ARK individual-level genotype data. For non-298 resident SSA dataset comparisons, the LD reference panel (LD<sub>NONRES</sub>) was constructed using 299 UKB individual-level genotype data. For the combined datasets comparison, the LD reference 300 panel (LD<sub>ALL</sub>) was constructed using AWI-Gen, ARK, and UKB individual-level genotype 301 data. 302 Fine-mapping and lead SNPs For each locus with a lead SNP with a P-value below 5x10<sup>-08</sup>, fine-mapping was conducted 303 304 using the H3ABioNet H3AGWAS pipeline and implementing a stepwise model selection 305 procedure through GCTA (Yang et al., 2011, 2012; Brandenburg et al., 2022a) to identify independently associated SNPs. Subsequently, we utilized the FINEMAP software (Version 306 307 1.4) (Benner et al., 2016), considering one causal variant, to define the credible set with 99% 308 confidence using a stochastic approach (Benner et al., 2016). 309 Conditional analyses (GCTA) 310 Conditional analyses used the GCTA software implemented within the H3AGWAS pipeline, 311 with summary statistics obtained from the meta-analyses as input. In these analyses, the lead 312 SNPs identified in each meta-analysis were conditioned upon lead SNPs found in previously 313 published studies. Changes in the p-value, both increasing or decreasing significance, of the 314 lead SNP, confirmed a relationship between the two SNPs. 315 Replication of previous findings Replication was performed according to the following criteria: 1) Exact replication: if any 316 317 genome-wide significant lead SNPs found in CKD-Gen-EA and CKD-Gen-MA reached 318 statistical significance (p<0.05) in Meta<sub>SSA</sub>, Meta<sub>NONRES</sub> or Meta<sub>ALL</sub> after Bonferroni correction 319 (A total of 60 independent lead SNPs were identified in the CKD-Gen datasets, of which 55 320 lead SNPs were from CKD-Gen-EA and 57 lead SNPs were from CKD-Gen-MA) and that the 321 lead SNPs have same direction of effect. 2) LD Window replication: for a given genome-wide 322 significant SNP found in the CKD-Gen datasets, SNPs were extracted from Metassa, 323 Meta<sub>NONRES</sub> and Meta<sub>ALL</sub> that are in LD with the said CKD-Gen lead SNP. LD pruning used the clump procedure in PLINK (Version 1.9) (r2 = 0.1, windows size 1000 kb,  $P_1 = 5 \times 10^{-08}$ ,  $P_2$ 324 = 0.1). The lowest p-value(s) from SNPs within the given LD window were extracted and this 325 LD window was considered statistically significant if the p-value was less than  $5 \times 10^{-04}$  in both 326 327 datasets. Additionally, the direction of effect between the CKD-Gen and Meta-datasets

329

330

331

332

333

334

335

336

337

338339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

(Metassa, Metanonres and Metaall) must be consistent. Conditional analyses were performed between the genome-wide significant SNP(s) in CKD-Gen and lead SNP in our meta-analyses to confirm the replication. For replication, the findings from Metassa were compared to CKD-Gen-MA and CKD-Gen-EA, and the findings from Meta<sub>NONRES</sub> and Meta<sub>ALL</sub> were only compared to CKD-Gen-EA to avoid sample overlaps within the CKD-Gen datasets (as CKD-Gen-AA is contained within CKD-Gen-MA). Annotation and Expression Quantitative Trait Locus (eQTL) analysis Functional annotation of genome-wide significant SNPs found in Metassa, Metanonres and/or Meta<sub>ALL</sub> was done using the ANNOVAR software (Wang et al., 2010). eQTL analysis was performed using the database of cis-eQTLs in both glomerular and tubulointerstitial tissues, derived from participants in the Nephrotic Syndrome Study Network (NEPTUNE) using SNPs with false discovery rate (FDR) < 0.05 ( Han et al. 2023). In this analysis a 1000kb window was defined around each genome-wide significant locus and an eQTL was considered significant if the LD (r2) was ≥0.01 between the lead SNP and significant eQTL, LD computation used the genetics data from the African populations from the 1000 Genomes Project (v5a, hg19) (Auton et al., 2015; Sudmant et al., 2015). Polygenic Scores PGS were computed for each dataset independently (AWI-Agincourt, AWI- Dikgale, AWI-Nanoro, AWI-Nairobi, AWI-Navrongo, AWI-Soweto ARK-Agincourt, UKB-African and UKB-Caribbean). The effect sizes from 3 previous studies were used: CKD-Gen-AA, CKD-Gen-MA, and CKD-Gen-EA. PRS-CS (Ge et al., 2019), software that estimates posterior SNP effect sizes by implementing continuous shrinkage (CS) priors, was used to calculate the PGS. As external LD references are required for this analysis, the African LD data derived from the 1000 Genomes Project by the PRScs project was used for this purpose (accessible at https://github.com/getian107/PRScs). The PGS values were regressed against the residualized UACR value in a linear regression model that adjusted for age, sex, and the first five principal components to assess the performance of PGS.

## **Results**

357

358

### Study participants and phenotype data

- 359 Genomic and phenotypic data were accessible for 7,959 individuals in the AWI-Gen datasets,
- 360 1,011 individuals in the ARK dataset, and 2,916 individuals in the UK-Biobank dataset with
- 361 1,205 individuals and 1,711 individuals in UKB-African and UKB-Caribbean respectively
- 362 (Supplementary Figure S1). CKD-Gen AA was a meta-analysis of 7 studies including 6,795
- individuals in total. Overall, there was a higher prevalence of albuminuria (17.9%; median
- 364 UACR 1.01mg/mmol) among individuals from the UKB with African and Caribbean ancestry
- compared to individuals residing in SSA, where notable regional differences were observed.
- 366 The highest prevalence of albuminuria occurred in AWI-Agincourt, South Africa (14.1%;
- median UACR 0.59mg/mmol) while the lowest prevalence occurred in AWI-Nanoro, West
- 368 Africa (prevalence of albuminuria 4.5%, median UACR 0.35 mg/mmol) (**Table 1**).

### 369 **Meta-analysis**

- 370 Meta-analyses were conducted to investigate the genetics of UACR in resident Sub-Saharan
- 371 African datasets (Metassa) (Figure 2a), non-resident Sub-Saharan African datasets
- 372 (Meta<sub>NONRES</sub>) (**Figure 2b**) and all African ancestry datasets (Meta<sub>ALL</sub>) (**Figure 2c**).
- No genomic inflation was observed for the individual-dataset association testing performed on
- 374 the 9 datasets. All genomic inflation factors (lambda) were below 1.1. This was visually
- confirmed on the dataset specific QQ-plots and Manhattan plots (Supplementary Figure S2
- and Figure S3(a-i)). Dataset-specific significant findings are reported in Supplementary
- 377 **Table 2** and **Supplementary Figure S4(a-c)**.
- One genome-wide significant locus with the lead SNP rs9505286 (p=4.3.10<sup>-08</sup>) was identified
- in Metassa on chromosome 6. (**Figure 3a**). One genome wide significant locus with the lead
- 380 SNP rs73404549 was identified on chromosome 11 in Meta<sub>NONRES</sub> (p=5.6.10<sup>-11</sup>) and Meta<sub>ALL</sub>
- 381 (p= $7.7 ext{ } 10^{-13}$ ) (**Table 2, Figure 3b and 3c**)
- 382 SNP rs9505286 (chr6:7820353) is located in the intronic regions of *BMP6*. Two SNPs were
- identified in the 95% credible set using FINEMAP (Figure 3a, Supplementary Table 4).
- eQTLs in the region were found to be associated with the expression of two genes *RREB1* and
- 385 BMP6 (Table 2; Supplementary Figure S5; Supplementary Table 3, Supplementary Table
- 386 **5**).
- 387 SNP rs73404549 (chr11:5320654) is located near the *HBE1*, *OR51B4*, and *HBB* genes. This
- 388 signal is primarily driven by results from West African ancestry datasets in the Meta<sub>NONRES</sub> and
- Meta<sub>ALL</sub> (**Figure 3b and 3c, Supplementary Figure S6**). Notably, this SNP is monomorphic

- in the Southern African and East African datasets. Furthermore, rs73404549 is in LD with
- rs334 ( $r^2$ =0.52; 72,422 bp apart), the SNP that defines the sickle cell mutation (HbS). SNP
- rs334 was also significant in Meta<sub>ALL</sub> (P<sub>ALL</sub>=8.55x10<sup>-9</sup>).
- 394 In the window of 1000kb around rs73404549, SNPs in the region colocalized with gene
- 395 expression of TRIM6 and STIM1 in glomerular and tubulointerstitial tissues (Table 2,
- 396 **Supplementary Table 5**).

397

- 398 Seven and two SNPs were identified in the 95 % credible set using FINEMAP in Meta<sub>NONRES</sub>
- and Meta<sub>ALL</sub> results respectively (**Supplementary Table 3**; **Supplementary Figure S6**).

### 400 Replication of previous findings

- 401 Replication analysis confirmed associations in three previously identified regions in *THBS3*,
- 402 *SPATA5L1/GATM*, and *ARL15* (**Supplementary Table 3**).
- 403 In the *THBS3* region, the Meta<sub>ALL</sub> meta-analysis rs370545 was the lead SNP in our dataset,
- with a P-value of 1x10<sup>-04</sup>. However, a conditional analysis using rs2974937 (lead SNP in CKD-
- Gen-EA) resulted in a decrease in significance level (P<sub>conditional analysis</sub>=0.85). This suggests that
- 406 the association in the *THBS3* region was driven by rs2974937 in Meta<sub>ALL</sub> even though it was
- not the lead SNP in this region (**Supplementary Table 4**; **Supplementary Figure 7**).
- 408 In the ARL15 region, a statistically significant association signal was observed in Metassa
- 409 (rs1664781, P=1.8x10<sup>-04</sup>). Conditional analysis using rs1694068 (lead SNP in CDK-Gen-EA)
- 410 revealed a reduction in P-value for rs1664781 (P<sub>conditional analysis</sub>=0.87), suggesting that
- 411 rs1694068 and rs1664781 are in LD thus confirming the association in this region
- 412 (Supplementary Table 4, Supplementary Figure 8).
- In the SPATA5L1/GATM region, the Meta<sub>ALL</sub> meta-analysis identified rs1694067 as the lead
- SNP in this region with a P-value of  $7.0 \times 10^{-05}$ . Furthermore, the lead SNP rs1153847 identified
- in CKD-Gen-EA, rs1153847, was present in our dataset, and its association was replicated
- 416 (P<sub>Bonferoni adjusted</sub>=0.04). For the window-based replication, a conditional analysis using
- 417 rs2467858 (genome-wide significant SNP in CKD-Gen-EA), a reduced P-value was observed
- 418 (P<sub>conditional analysis</sub>=0.87) confirming rs1694067 and rs2467858 are in LD and replicated the
- 419 CKD-Gen signal. (Supplementary Table 4; Supplementary Figure 9).

### Polygenic score analyses

420

- 421 The variance explained by the PGS for UACR residuals was between 0% and 0.82%. PGS
- 422 constructed using the betas from CKD-Gen-EA and CKD-Gen-MA performed better for the

- 423 non-SSA resident datasets, particularly in the UKB-African, showing the best predictivity (%
- variance: 0.82,  $p=1\times10^{-04}$ ) and statistically significant correlation between the PGS and the
- 425 UACR residual (**Figure 4, Supplementary Table S6**).
- 426 Using the PGS constructed from CKD-Gen-MA, ARK-Agincourt (% variance: 0.61, P=0.01)
- and AWI-Agincourt (%variance: 0.58, P=0.002) demonstrated better predictivity in SSA
- 428 populations. PGS constructed from CKD-Gen-AA did not improve the variance explained.
- 429 Variance explained was lower using PGS constructed from CKD-GEN-AA than CKD-Gen-
- 430 MA or CKD-Gen-EA.

432

# **Discussion**

- This study is the first GWAS for UACR conducted in Sub-Saharan African populations. Two
- 434 genomic regions were identified to be significantly associated with UACR among 8,970
- participants from West, East, and Southern Africa and among 9,705 non-resident African-
- ancestry participants from the UK Biobank and CKD-Gen Consortium.
- For the first locus, the SNP rs9505286, reached genome-wide significance in resident African
- individuals (MetaSSA) and is located in the intronic region of BMP6. eQTLs in LD with
- 439 rs9505286 were found to be associated with expression of two genes, namely bone
- 440 morphogenetic protein 6 (BMP6) and ras-responsive element binding protein 1 (RREB1). Both
- genes are plausibly linked with kidney disease. BMP6 encodes a secreted ligand of the
- transforming growth factor (TGF-beta) superfamily of proteins, of which TGF-B1 is one of the
- 443 most important regulators of kidney fibrosis, the pathological hallmark of irreversible loss of
- kidney function in CKD (Dendooven et al., 2011; Jenkins and Fraser, 2011). TGF-B1 is highly
- expressed in various fibrotic kidney diseases, including diabetic nephropathy (DN),
- hypertensive nephropathy, obstructive kidney disease, autosomal dominant polycystic kidney
- disease, immunoglobulin A nephropathy, crescentic glomerulonephritis, and focal segmental
- 448 glomerulosclerosis. Because of its pivotal role in mediating kidney fibrosis, TGF-B1 is a
- potential target for drug discovery, and these results point towards similar potential in African
- 450 populations for further exploration. RREB1, initially identified as a repressor of the
- angiotensinogen gene, is associated with type 2 diabetes in African Americans with end stage
- kidney disease(Bonomo et al., 2014). *RREB1* polymorphisms have been shown to interact with
- 453 APOL1, and are implicated in fat distribution and fasting glucose, a potential explanation for
- 454 the association with type 2 diabetes. As obesity and type 2 diabetes prevalence emerge in many
- 455 African communities undergoing rapid sociodemographic transition, these findings must

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

inform future work (Bonomo et al., 2014). Unfortunately, neither of the eQTLs has strong linkage disequilibrium (LD) support with the lead SNP rs9505286 (see Supplementary Table 5). Variability of kidney function, confounding factors and allele frequency differences between datasets may explain why the rs9505286 signal was not replicated in Meta<sub>ALL</sub> or Meta<sub>NONRES</sub> (Marigorta et al., 2018). For the second locus, the SNP rs73404549 was found to be statistically significant in nonresident individuals with African Ancestry (Meta<sub>NONRES</sub>) and overall (Meta<sub>ALL</sub>), but not in Sub-Saharan African individuals (Metassa). This can be explained by the fact that the variant allele of rs73404549 is extremely rare or absent in East and South African populations. This SNP was found to be in linkage disequilibrium with rs334, the sickle cell trait (HbS) in the HBB gene. The HbS mutation has been linked to malaria resistance among heterozygotes, with differences in allele frequency attributed to variations in selection pressures between Bantuspeaking populations in West and South/East Africa (Gurdasani et al., 2019; Choudhury et al., 2020). Notably, sickle cell trait and rs334 had been associated with various kidney function (eGFR) and kidney disease traits, including albuminuria, and chronic and end-stage kidney disease in African, African American and US Hispanic/Latino populations (Naik et al., 2014; Gurdasani et al., 2019; Fatumo et al., 2020; Masimango et al., 2022). Furthermore, an interaction between APOL1 high-risk genotypes and the sickle cell trait enhances the risk for low eGFR(Masimango et al., 2022). In addition to the HBB region, our GWAS revealed transferability of three previously identified signals. Of the 60 UACR-associated loci identified in European and Multi-Ancestry studies, only three were replicated, including variants in GATM. This region was also associated with eGFR in a Ugandan population (Fatumo et al., 2020). We also replicated the association with ARL15 in the region of chromosome 1. ARL15 is a regulator of Mg2+ transport thereby promoting the complex N-glycosylation of cyclin M proteins (CNNM 1-4) and could play a role in the pathogenesis of hypertension mediated via altered tubular handling of magnesium in the kidney (Zolotarov et al., 2021). Allelic heterogeneity is high in African ancestry populations, as demonstrated by the high genetic diversity in our study (Supplementary Fig. 1). However, analysis of regional subgroups using meta-analysis (residents of South, West, or East Africa) did not reveal significant population-specific signatures (p<5e-8), likely due to small sample sizes within these subgroups (Supplementary Fig. 10a, 10b, 3i). Interestingly, meta-analysis under a random-effects model that allows for heterogeneity in allelic effects between regions

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

(Meta<sub>ALL</sub><sup>RE</sup>) did not improve the detection of specific signals already observed with the fixedeffects methods for HBB (Supplementary Figure S11). Consequently, the heterogeneity observed might be explained primarily by variations in linkage disequilibrium or environmental factors rather than by the effect of a specific allele, such as the presence or absence of sickle cell trait (Adriani Nikolakopoulou et al., 2014; Kuchenbaecker et al., 2019; Choudhury et al., 2020). The transferability of PGS developed using the effect sizes quantified in three previous association studies in European ancestry, African ancestry and multi-ancestry populations showed limited predictability, explaining less than 1% of the variability in UACR. PGS in resident African populations (AWI-Gen and ARK) explained between 0.58% and 0.60% of the variance of UACR compared to UKB-African, where best prediction was observed (0.80%). The poor predictability of UACR using summary statistics derived from African Americans was likely due to the small sample size of the discovery dataset. Unfortunately, there have been few studies on PGS approaches to compare findings with, and the genetic heritability of UACR is relatively low, estimated at 4.3% (Teumer et al., 2019). The limited transferability of PGS and previous GWAS signals across ancestral groups could be due to differences in genetic architecture and/or pleiotropic effects. Different demographic histories and genetic selection pressures between European and African populations could modify the ability to replicate previous GWAS results due to differences in allele frequencies between non-African and African populations, with generally lower LDs in African genomes. Environmental factors and variability in the prevalence and aetiology of kidney - and diseaserelated risk factors such as diabetes and hypertension (Fatumo et al., 2020) could also influence the genetic architecture of kidney disease in Africans populations (Limou et al., 2014; Teumer et al., 2019; Brandenburg et al., 2022b). Selection pressures have increased the frequencies APOL1 kidney risk variants and HbS due to their protective properties in areas of Africa where trypanosomiasis and malaria are endemic. This may have contributed to shaping genetic susceptibility to kidney disease in African individuals. In our study, the APOL1 gene region did not exhibit significant associations with UACR. The indel rs71785313 was not imputed using the African Sanger reference for imputation, and a specific study had previously been published to describe APOL1 variant distribution in the AWI-Gen dataset using other imputation panels, but the locus did not reach genomic significance (5e<sup>-8</sup>) for association with eGFR and UACR (Brandenburg et al., 2022b). While the burden of CKD in SSA is high, it is noteworthy that no prior GWAS on UACR has been conducted on the continent. Despite its uniqueness, our study is limited by its relatively

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

modest sample size, which impacts statistical power to detect small-effect associations reaching genome-wide significance thresholds. Kidney and disease markers were measured at a single time point, and spot urine albumin and creatine levels are sensitive to incident infections and other environmental factors that could affect the prevalence of albuminuria. It is important to note that our study populations are mainly treatment naïve in relation to kidney disease and other cardiometabolic conditions, which may be an advantage in detecting genetic associations (Pereira et al., 2021). Other studies, based on lipid-associated loci, attributed non-transferability of associated loci to pleiotropic effects, gene-environment interactions, and also to variability in allele frequencies and LD patterns (Kuchenbaecker et al., 2019; Choudhury et al., 2022), as we hypothesize for UACR. In conclusion, this study describes genetic associations with UACR in a unique SSA cohort and non-resident individuals with African ancestry. CKD in African populations remains understudied but from available data, hypertension, rather than diabetes is the most commonly associated risk factor and in some regions, up to 60% of people with CKD do not have an associated "traditional" risk factor common to high-income settings, suggesting alternate underlying molecular pathways or aetiologies for CKD (Kalyesubula et al., 2018; Nakanga et al., 2019; Muiru et al., 2020). Our study identified two novel SNPs associated with UACR in populations of African ancestry. We further replicated three known UACR-associated loci. Regional genetic diversity due to different selection pressures appear to play a role in the genetic aetiology of CKD across the African continent. These factors likely contribute to the limited transferability of previous association signals and the poor transfer of polygenic scores developed in non-African populations to African populations. Larger genomic studies are necessary to better understand the genetic architecture of kidney function and chronic kidney disease across different African populations and inform region-specific kidney risk profiles. As demonstrated in this study, the low genetic heritability of UACR limits the predictive power of genetic risk scores (GRS) for kidney disease in our setting. It is critical for future research to address these gaps by modelling integrative risk scores that incorporate locally relevant clinical risk factors that are powerful predictors of kidney disease, multiple kidney phenotypes (eGFR<sub>cystatin C</sub>, eGFR<sub>creatinine</sub>, eGFR<sub>creatinine + cystatin C</sub>, albuminuria, Blood urea nitrogen), using multi-omics (Eddy et al., 2020), and the impacts of African-specific genetic risk for kidney disease, such as APOL1 high-risk genotypes and sickle cell trait or disease(Naik et al., 2014; Friedman and Pollak, 2016; Brandenburg et al., 2022b).

Disclosure statement

The authors have nothing to disclose.

**Ethics Statement** 

557

558

559

560

- This study received approval from the Human Research Ethics Committee (Medical),
- University of the Witwatersrand/South Africa (M121029; M170880; M160939), the approval
- of the Centre Muraz Institutional Ethics Committee/Burkina Faso (015-2014/CE- CM) and the
- approval of the National Ethics Committee For Health Research/Burkina Faso (2014-08-096),
- the Ghana Health Service Ethics Review Committee (ID No: GHS-ERC:05/05/2015), the
- 566 AMREF Health Ethics and Scientific Review Committee in Kenya (approval no. P114/2014)
- and the Navrongo Institutional Review Board (ID No: NHRCIRB178). All the participants
- signed an Informed Consent Form before any study procedure was performed.

### **Conflict of Interest**

571 None

569

570

572573

579

580 581

### Acknowledgement

- We acknowledge the sterling contributions of our field workers, phlebotomists, laboratory
- scientists, administrators, data personnel, and all other staff who contributed to the AWI-Gen
- and ARK data and sample collection, processing, storage, and shipping, and the participants
- 577 who generously agreed to be part of the studies. The UK Biobank kindly shared data under the
- 578 UK Biobank Resource Application Number 63215 and approved submission of the paper.

## **Funding**

- This study was funded by the National Institutes of Health (NIH) through the H3Africa AWI-
- 583 Gen project (NIH grant number U54HG006938)). AWI-Gen is supported by the National
- Human Genome Research Institute (NHGRI), Eunice Kennedy Shriver National Institute of
- 585 Child Health & Human Development (NICHD), and Office of the Director (OD) at the
- National Institutes of Health. PB is funded by the National Research Foundation/The World
- Academy of Sciences "African Renaissance Doctoral Fellowship" (Grant no. 100004). JTB is
- supported by grants from the National Human Genome Research Institute (U54HG006938) as
- part of the H3A Consortium (AWI-Gen); and the Science For African Foundation REACCT-
- 590 CAN Grant (Del-22-008). MR is the South African Research Chair in Genomics and
- 591 Bioinformatics of African populations hosted by the University of the Witwatersrand
- 592 (SARChI), funded by the South African Department of Science and Innovation, and

- 593 administered by the National Research Foundation. WCC is supported by the Research
- Networks for Health Innovations in sub-Saharan Africa Funding Initiative of the German
- 595 Federal Ministry of Education and Research (RHISSA) Grant and the Science For African
- 596 Foundation REACCT-CAN Grant (Del-22-008). The ARK study was jointly funded by the
- 597 South African MRC, MRC UK (via the Newton Fund), and GSK Africa Non-Communicable
- 598 Disease Open Lab (via a supporting grant; project number 074). The views expressed in this
- manuscript do not necessarily reflect the views of the funders.
- **Author Contributions**
- JTB and MR designed the study, JTB performed the analyses and wrote the first draft. WCC,
- MR, AM, SH and JF made significant contributions to guiding the analyses and interpreting
- 603 the results, as well as writing and reviewing the manuscript. All authors read, edited and
- approved the manuscript.

621

### Data availability statement

- Summary statistics are available in the GWAS catalog (XXX) and scripts are available from
- the corresponding authors. The AWI-Gen data set is available from the European Genome-
- 609 phenome Archive (EGA) database (https://ega-archive.org/), accession number
- 610 EGAS00001002482 (phenotype dataset: EGAD00001006425; genotype dataset:
- 611 EGAD00010001996). The availability of these datasets is subject to controlled access through
- 612 the Data and Biospecimen Access Committee of the H3Africa Consortium. ARK data is
- available in WIReDSpace repository on request (https://wiredspace.wits.ac.za/),
- 614 https://doi.org/10.54223/uniwitwatersrand-10539-33016 35
- Data are available under the terms of the Creative Commons Zero "No rights reserved" data
- waiver (CC0 1.0 Public domain dedication). The processed data generated in this study are
- provided in Supplementary Material. Permission was obtained to access the genotype and
- phenotype dataset for UKBB (research project number: 63215).
- 619 Publicly available databases include Teumer et al. in CKD-GEN consortium website:
- 620 https://ckdgen.imbi.uni-freiburg.de/.

#### **Tables**

622

623624

625

626

627

**Table 1: Study participants and phenotype data.** Participant characteristics for each AWI-Gen study site, ARK-Agincourt and UKB-African and UKB-Caribbean, with phenotype distributions of UACR (median) and covariables used in the study.

Dataset	Sample size	Country of residence	<sup>1</sup> Age (years)	Males (%)	<sup>2</sup> UACR	<sup>3</sup> Albuminuria (%)
Non-resident in <sup>4</sup> SSA	9,705					
5CKD-Gen-AA	6,795	USA				
<sup>6</sup> UKB-African	1,205	UK	51.8	48.5	1.10 (1.70)	20.0
<sup>7</sup> UKB-Caribbean	1,711	UK	52.8	59.6	0.93 (1.44)	16.4
<sup>8</sup> UKB-All	2,916	UK	52.4	55.0	1.01 (1.55)	17.9
Resident in SSA	8,970					
9AWI-Nanoro	1,702	Burkina Faso	49.6	50.8	0.35 (0.44)	4.9
10AWI-Navrongo	1,548	Ghana	51.1	54.4	0.41(0.48)	6.7
11AWI-Nairobi	1,481	Kenya	48.8	54.0	0.63 (0.67)	11.4
<sup>12</sup> AWI-Agincourt	1,545	South Africa	54.3	59.8	0.59 (0.99)	14.1
<sup>13</sup> AWI-Dikgale	917	South Africa	52.1	68.3	0.63 (0.51)	10.4
14AWI-Soweto	766	South Africa	49.5	100.0	0.36 (0.57)	11.4
AWI-All	7,959		50.9	51.0	0.48 (0.51)	9.5
15 ARK-Agincourt	1,011	South Africa	38.8	58.0	0.57 (0.94)	13.4
Total	17,664		50.3	52.6	0.59 (0.85)	11.9

<sup>&</sup>lt;sup>1</sup>data reported as the mean.

<sup>&</sup>lt;sup>2</sup>UACR: urine albumin: creatinine ratio: mg/mmol; reported as median (interquartile range).

<sup>&</sup>lt;sup>3</sup>Albuminuria: UACR>3.0mg/mmol.

<sup>&</sup>lt;sup>4</sup>SSA: Sub-Saharan Africa.

<sup>&</sup>lt;sup>5</sup>CKD-Gen Consortium: African American Ancestry individuals. CKD-GEN-AA data are summary statistics of meta-analysis from Teumer et al. downloadable at the CKD-GEN consortium website (http://ckdgen.imbi.uni-freiburg.de/), information relative to samples had been reported in relevant papers.

<sup>&</sup>lt;sup>6</sup>UKB Biobank: Individuals of self-reported African Ancestry; <sup>7</sup>self-reported Caribbean Ancestry; <sup>8</sup>self-reported African and Caribbean Ancestry.

<sup>&</sup>lt;sup>9</sup>Africa Wits -INDEPTH partnership for Genomic Studies (AWI): individuals of African Ancestry from <sup>9,10</sup>West Africa; <sup>11</sup>East Africa; <sup>12</sup><sup>14</sup>South Africa.

<sup>&</sup>lt;sup>15</sup>African Research on Kidney Disease (ARK) Study: South Africa

**Table 2:** Lead genome-wide significantly associated SNPs for sub-Saharan African population meta-analysis (Meta<sub>SSA</sub>), non-resident African ancestry population meta-analysis (Meta<sub>NONRES</sub>) and the combined African ancestry population meta-analysis (Meta<sub>ALL</sub>).

							Metassa		Metanonres			Meta <sub>ALL</sub>			
Chr	bp	rsID	Genes	eQTL (genes)	EA	NEA	beta (se)	P	EAF	beta (se)	P	EAF	beta (se)	P (beta, se)	EAF
6	7820353	rs9505286	intronic: BMP6	RREB1,BM P6	T	С	0.19 (0.03)	4.3e- 08	0.95	-0.05 (0.07)	0.17	0.96	-0.13 (0.03)	7.2e-07	0.96
11	5320654	rs73404549	intergenic: HBE1, OR51B4	TRIM6,TRI M5,STIM1, OR51E2,A C104389.2 8,PRKCDB P,UBQLNL ,OR51E1,H BE1,AC087 380.14,OR5 2K3P,RP11 - 23F23.3,TR IM6- TRIM34,TR IM34,RP11 -290F24.6	Т	С	0.17 (0.06)	3.2e- 03	0.05	0.21 (0.06)	5.6e-11	0.05	0.2 (0.04)	7.7e-13	0.05

Chr: chromosome (hg19)

640641

642

bp: position coordinates rsID: SNPs identification

Genes: genes annotation using ANNOVAR

eQTL: gene's transcript is significantly associated with nearby SNP positions (1000kb and LD>0.01)

EA: Effect allele
NEA: non effect allele

beta (se): effect size and standard error

P: significance of association EAF: Effect allele frequency

657658

659

660661

662

663 664

665

666

667668669

670

671672

673674675

676

677

678

679

680

681

682

683

684

685

686

687

688

**Figure Legends** Figure 1: Study design showing data sources, the analysis strategy and post-GWAS analysis approach. Figure 2: Manhattan plot - GWAS of UACR in the (a) Metassa (b) Metanonres (c) Metaall datasets using the fixed effect model. Lead genome-wide significant SNPs (P<5x10<sup>-08</sup>) and gene annotations are highlighted. Figure 3: Regional plot using LocusZoom of genome-wide significant SNPs found in metaanalyses using the fixed effect model, (a) rs9505286 from the result of Metassa, (b) rs9966824 from the result Meta<sub>NONRES</sub> (c) rs9966824 from the result Meta<sub>ALL</sub>. Figure 4. Percent variance explained between PGS and residual phenotypes computed using age, sex and 5 PCs. Key: The negative relationship between PGS and the phenotype in the result of the linear model, \* P<0.05, \*\* P<0.01 and \*\* P<0.001. Details in Supplementary Table 6 References Adam, Y., Sadeeq, S., Kumuthini, J., Ajayi, O., Wells, G., Solomon, R., et al. (2022). Polygenic Risk Score in African populations: progress and challenges. F1000Res 11, 175. doi: 10.12688/f1000research.76218.2 Adriani Nikolakopoulou, Dimitris Mavridis, and Georgia Salanti (2014). How to interpret meta-analysis models: fixed effect and random effects meta-analyses. Evid Based Ment Health 17, 64. doi: 10.1136/eb-2014-101794 Alexander, D. H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of unrelated individuals. Genome Res 19, 1655–1664. doi: ancestry in 10.1101/gr.094052.109 Ali, S. A., Soo, C., Agongo, G., Alberts, M., Amenga-Etego, L., Boua, R. P., et al. (2018). Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study. Global Health Action 11, 1507133. doi: 10.1080/16549716.2018.1507133

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

Auton, A., Abecasis, G. R., Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., et al. (2015). A global reference for human genetic variation. *Nature* 526, 68–74. doi: 10.1038/nature15393 Baichoo, S., Souilmi, Y., Panji, S., Botha, G., Meintjes, A., Hazelhurst, S., et al. (2018). Developing reproducible bioinformatics analysis workflows for heterogeneous computing environments to support African genomics. BMC Bioinformatics 19, 457. doi: 10.1186/s12859-018-2446-1 Benner, C., Spencer, C. C. A., Havulinna, A. S., Salomaa, V., Ripatti, S., and Pirinen, M. (2016). FINEMAP: efficient variable selection using summary data from genome-wide association studies. Bioinformatics (Oxford, England) 32, 1493–1501. doi: 10.1093/bioinformatics/btw018 Böger, C. A., Chen, M.-H., Tin, A., Olden, M., Köttgen, A., de Boer, I. H., et al. (2011). CUBN is a gene locus for albuminuria. Journal of the American Society of Nephrology: JASN 22, 555–570. doi: 10.1681/ASN.2010060598 Bonomo, J. A., Guan, M., Ng, M. C. Y., Palmer, N. D., Hicks, P. J., Keaton, J. M., et al. (2014). The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease. Hum Mol Genet 23, 6441-6447. doi: 10.1093/hmg/ddu362 Borenstein, M., Hedges, L. V., Higgins, J. P. T., and Rothstein, H. R. (2010). A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods 1, 97–111. doi: 10.1002/jrsm.12 Brandenburg, J.-T., Clark, L., Botha, G., Panji, S., Baichoo, S., Fields, C., et al. (2022a). H3AGWAS: a portable workflow for genome wide association studies. BMC Bioinformatics 23, 498. doi: 10.1186/s12859-022-05034-w Brandenburg, J.-T., Govender, M. A., Winkler, C. A., Boua, P. R., Agongo, G., Fabian, J., et al. (2022b). Apolipoprotein L1 High-Risk Genotypes and Albuminuria in Sub-Saharan African Populations. Clin J Am Soc Nephrol 17, 798–808. doi: 10.2215/CJN.14321121 Casanova, F., Tyrrell, J., Beaumont, R. N., Ji, Y., Jones, S. E., Hattersley, A. T., et al. (2019). A genome-wide association study implicates multiple mechanisms influencing raised

718 urinary albumin-creatinine ratio. Human Molecular Genetics 28, 4197-4207. doi: 719 10.1093/hmg/ddz243 720 Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., and Lee, J. J. (2015). 721 Second-generation PLINK: rising to the challenge of larger and richer datasets. 722 Gigascience 4, 7. doi: 10.1186/s13742-015-0047-8 723 Choudhury, A., Aron, S., Botigué, L. R., Sengupta, D., Botha, G., Bensellak, T., et al. (2020). 724 High-depth African genomes inform human migration and health. Nature 586, 741-725 748. doi: 10.1038/s41586-020-2859-7 726 Choudhury, A., Brandenburg, J.-T., Chikowore, T., Sengupta, D., Boua, P. R., Crowther, N. 727 J., et al. (2022). Meta-analysis of sub-Saharan African studies provides insights into 728 genetic architecture of lipid traits. Nature Communications 13, 2578. doi: 729 10.1038/s41467-022-30098-w 730 Craik, A., Gondwe, M., Mayindi, N., Chipungu, S., Khoza, B., Gomez-Olivo, X., et al. 731 (2023). Forgotten but not gone in rural South Africa: Urinary schistosomiasis and 732 implications for chronic kidney disease screening in endemic countries [version 3; peer 733 review: 2 approved]. Wellcome Open Research 8. doi: 734 10.12688/wellcomeopenres.18650.3 735 Dendooven, A., van Oostrom, O., van der Giezen, D. M., Leeuwis, J. W., Snijckers, C., Joles, 736 J. A., et al. (2011). Loss of endogenous bone morphogenetic protein-6 aggravates renal 737 fibrosis. Am J Pathol 178, 1069–1079. doi: 10.1016/j.ajpath.2010.12.005 738 Eddy, S., Mariani, L. H., and Kretzler, M. (2020). Integrated multi-omics approaches to 739 improve classification of chronic kidney disease. Nature Reviews Nephrology 16, 657– 740 668. doi: 10.1038/s41581-020-0286-5 741 Fabian, J., Gondwe, M., Mayindi, N., Chipungu, S., Khoza, B., Gaylard, P., et al. (2022). 742 Chronic kidney disease (CKD) and associated risk in rural South Africa: a population-743 based cohort study [version 2; peer review: 2 approved]. Wellcome Open Research 7. 744 doi: 10.12688/wellcomeopenres.18016.2

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

Fatumo, S., Chikowore, T., Kalyesubula, R., Nsubuga, R., Asiki, G., Nashiru, O., et al. (2020). Discovery and fine-mapping of kidney function loci in first genome-wide association study in Africans. doi: 10.1101/2020.06.09.142463 Friedman, D. J., and Pollak, M. R. (2016). Apolipoprotein L1 and Kidney Disease in African Americans. Trends in endocrinology and metabolism: TEM 27, 204-215. doi: 10.1016/j.tem.2016.02.002 GBD Chronic Kidney Disease Collaboration, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., et al. (2020). Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England) 395, 709-733. doi: 10.1016/S0140-6736(20)30045-3 Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A., and Smoller, J. W. (2019). Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nature Communications* 10, 1776. doi: 10.1038/s41467-019-09718-5 George, J. A., Brandenburg, J.-T., Fabian, J., Crowther, N. J., Agongo, G., Alberts, M., et al. (2019). Kidney damage and associated risk factors in rural and urban sub-Saharan Africa (AWI-Gen): a cross-sectional population study. The Lancet Global Health 7, e1632-e1643. doi: 10.1016/S2214-109X(19)30443-7 Gomez, F., Hirbo, J., and Tishkoff, S. A. (2014). Genetic variation and adaptation in Africa: implications for human evolution and disease. Cold Spring Harbor perspectives in biology 6, a008524–a008524. doi: 10.1101/cshperspect.a008524 Gorski, M., van der Most, P. J., Teumer, A., Chu, A. Y., Li, M., Mijatovic, V., et al. (2017). 1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function. Scientific reports 7, 45040. doi: 10.1038/srep45040 Gurdasani, D., Carstensen, T., Fatumo, S., Chen, G., Franklin, C. S., Prado-Martinez, J., et al. (2019). Uganda Genome Resource Enables Insights into Population History and Genomic Discovery in Africa. Cell 179, 984-1002.e36. doi: 10.1016/j.cell.2019.10.004

772 Gurdasani, D., Carstensen, T., Tekola-Ayele, F., Pagani, L., Tachmazidou, I., Hatzikotoulas, 773 K., et al. (2015). The African Genome Variation Project shapes medical genetics in 774 Africa. Nature 517, 327–332. doi: 10.1038/nature13997 775 Haas, M. E., Aragam, K. G., Emdin, C. A., Bick, A. G., Hemani, G., Davey Smith, G., et al. 776 (2018). Genetic Association of Albuminuria with Cardiometabolic Disease and Blood 777 Pressure. American **Journal** of Human Genetics 103, 461–473. doi: 778 10.1016/j.ajhg.2018.08.004 779 Han, B., and Eskin, E. (2011). Random-effects model aimed at discovering associations in 780 meta-analysis of genome-wide association studies. American journal of human genetics 781 88, 586–598. doi: 10.1016/j.ajhg.2011.04.014 782 Han, S. K., McNulty, M. T., Benway, C. J., Wen, P., Greenberg, A., Onuchic-Whitford, A. C., 783 et al. (2023). Mapping genomic regulation of kidney disease and traits through high-784 resolution and interpretable eQTLs. Nature Communications 14, 2229. doi: 785 10.1038/s41467-023-37691-7 786 Hellwege, J. N., Velez Edwards, D. R., Giri, A., Qiu, C., Park, J., Torstenson, E. S., et al. 787 (2019). Mapping eGFR loci to the renal transcriptome and phenome in the VA Million 788 Veteran Program. Nature Communications 10, 3842. doi: 10.1038/s41467-019-11704-789 W 790 Jenkins, R. H., and Fraser, D. J. (2011). BMP-6 emerges as a potential major regulator of 791 fibrosis in the kidney. *Am J Pathol* 178, 964–965. doi: 10.1016/j.ajpath.2010.12.010 792 Kachuri, L., Chatterjee, N., Hirbo, J., Schaid, D. J., Martin, I., Kullo, I. J., et al. (2023). 793 Principles and methods for transferring polygenic risk scores across global populations. 794 Nature Reviews Genetics. doi: 10.1038/s41576-023-00637-2 795 Kalyesubula, R., Fabian, J., Nakanga, W., Newton, R., Ssebunnya, B., Prynn, J., et al. (2020). 796 How to estimate glomerular filtration rate in sub-Saharan Africa: design and methods 797 of the African Research into Kidney Diseases (ARK) study. BMC Nephrology 21, 20. 798 doi: 10.1186/s12882-020-1688-0

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

Kalyesubula, R., Hau, J. P., Asiki, G., Ssebunya, B., Kusemererwa, S., Seeley, J., et al. (2018). Impaired renal function in a rural Ugandan population cohort. Wellcome Open Res 3, 149. doi: 10.12688/wellcomeopenres.14863.3 Kamiza, A. B., Toure, S. M., Vujkovic, M., Machipisa, T., Soremekun, O. S., Kintu, C., et al. (2022). Transferability of genetic risk scores in African populations. Nature Medicine 28, 1163–1166. doi: 10.1038/s41591-022-01835-x Kamiza, A. B., Touré, S. M., Zhou, F., Soremekun, O., Cissé, C., Wélé, M., et al. (2023). Multitrait discovery and fine-mapping of lipid loci in 125,000 individuals of African ancestry. Nature Communications 14, 5403. doi: 10.1038/s41467-023-41271-0 Kaze, A. D., Ilori, T., Jaar, B. G., and Echouffo-Tcheugui, J. B. (2018). Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis. BMC Nephrology 19, 125. doi: 10.1186/s12882-018-0930-5 Köttgen, A., and Pattaro, C. (2020). The CKDGen Consortium: ten years of insights into the genetic basis of kidney function. Kidney International 97, 236-242. doi: 10.1016/j.kint.2019.10.027 Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 12, 7–11. doi: 10.1016/j.kisu.2021.11.003 Kuchenbaecker, K., Telkar, N., Reiker, T., Walters, R. G., Lin, K., Eriksson, A., et al. (2019). The transferability of lipid loci across African, Asian and European cohorts. Nature Communications 10. doi: 10.1038/s41467-019-12026-7 Lee, J., Lee, Y., Park, B., Won, S., Han, J. S., and Heo, N. J. (2018). Genome-wide association analysis identifies multiple loci associated with kidney disease-related traits in Korean populations. PLOS ONE 13, e0194044. Limou, S., Nelson, G. W., Kopp, J. B., and Winkler, C. A. (2014). APOL1 kidney risk alleles: population genetics and disease associations. Advances in chronic kidney disease 21, 426–433. doi: 10.1053/j.ackd.2014.06.005

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

Lin, B. M., Nadkarni, G. N., Tao, R., Graff, M., Fornage, M., Buyske, S., et al. (2019). Genetics of Chronic Kidney Disease Stages Across Ancestries: The PAGE Study. Frontiers in genetics 10, 494. doi: 10.3389/fgene.2019.00494 Loh, P.-R., Danecek, P., Palamara, P. F., Fuchsberger, C., A Reshef, Y., K Finucane, H., et al. (2016). Reference-based phasing using the Haplotype Reference Consortium panel. Nature Genetics 48, 1443–1448. doi: 10.1038/ng.3679 Mahajan, A., Rodan, A. R., Le, T. H., Gaulton, K. J., Haessler, J., Stilp, A. M., et al. (2016). Trans-ethnic Fine Mapping Highlights Kidney-Function Genes Linked to Salt 99. Sensitivity. American iournal ofhuman genetics 636–646. doi: 10.1016/j.ajhg.2016.07.012 Majara, L., Kalungi, A., Koen, N., Tsuo, K., Wang, Y., Gupta, R., et al. (2023). Low and differential polygenic score generalizability among African populations due largely to genetic diversity. Human Genetics and Genomics Advances 4, 100184. doi: 10.1016/j.xhgg.2023.100184 Marigorta, U. M., Rodríguez, J. A., Gibson, G., and Navarro, A. (2018). Replicability and Prediction: Lessons and Challenges from GWAS. Trends Genet 34, 504-517. doi: 10.1016/j.tig.2018.03.005 Martin, A. R., Gignoux, C. R., Walters, R. K., Wojcik, G. L., Neale, B. M., Gravel, S., et al. (2017). Human Demographic History Impacts Genetic Risk Prediction across Diverse Populations. Am J Hum Genet 100, 635–649. doi: 10.1016/j.ajhg.2017.03.004 Masimango, M. I., Jadoul, M., Binns-Roemer, E. A., David, V. A., Sumaili, E. K., Winkler, C. A., et al. (2022). APOL1 Renal Risk Variants and Sickle Cell Trait Associations With Reduced Kidney Function in a Large Congolese Population-Based Study. Kidney Int Rep 7, 474–482. doi: 10.1016/j.ekir.2021.09.018 Morris, A. P., Le, T. H., Wu, H., Akbarov, A., van der Most, P. J., Hemani, G., et al. (2019). Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies. Nature communications 10, 29. doi: 10.1038/s41467-018-07867-7

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

Muiru, A. N., Charlebois, E. D., Balzer, L. B., Kwarisiima, D., Elly, A., Black, D., et al. (2020). The epidemiology of chronic kidney disease (CKD) in rural East Africa: A populationbased study. PLoS One 15, e0229649. doi: 10.1371/journal.pone.0229649 Naik, R. P., Derebail, V. K., Grams, M. E., Franceschini, N., Auer, P. L., Peloso, G. M., et al. (2014). Association of Sickle Cell Trait With Chronic Kidney Disease and Albuminuria in African Americans. JAMA 312, 2115. doi: 10.1001/jama.2014.15063 Nakanga, W. P., Prynn, J. E., Banda, L., Kalyesubula, R., Tomlinson, L. A., Nyirenda, M., et al. (2019). Prevalence of impaired renal function among rural and urban populations: findings of a cross-sectional study in Malawi. Wellcome Open Res 4, 92. doi: 10.12688/wellcomeopenres.15255.1 Paria, S. S., Rahman, S. R., and Adhikari, K. (2022). fastman: A fast algorithm for visualizing **GWAS** results using Manhattan and Q-Q plots. bioRxiv. doi: 10.1101/2022.04.19.488738 Pattaro, C., Köttgen, A., Teumer, A., Garnaas, M., Böger, C. A., Fuchsberger, C., et al. (2012). Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS genetics 8, e1002584–e1002584. doi: 10.1371/journal.pgen.1002584 Pattaro, C., Teumer, A., Gorski, M., Chu, A. Y., Li, M., Mijatovic, V., et al. (2016). Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nature communications 7, 10023. doi: 10.1038/ncomms10023 Pereira, L., Mutesa, L., Tindana, P., and Ramsay, M. (2021). African genetic diversity and adaptation inform a precision medicine agenda. Nat Rev Genet 22, 284-306. doi: 10.1038/s41576-020-00306-8 Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., and Reich, D. (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nature Genetics 38, 904–909. doi: 10.1038/ng1847 Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., et al. (2010). LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336–2337. doi: 10.1093/bioinformatics/btq419

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906


907

908

Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics 81, 559–575. doi: 10.1086/519795 Ramsay, M., Crowther, N., Tambo, E., Agongo, G., Baloyi, V., Dikotope, S., et al. (2016). H3Africa AWI-Gen Collaborative Centre: a resource to study the interplay between genomic and environmental risk factors for cardiometabolic diseases in four sub-Saharan African countries. Global health, epidemiology and genomics 1, e20–e20. doi: 10.1017/gheg.2016.17 Sudmant, P. H., Rausch, T., Gardner, E. J., Handsaker, R. E., Abyzov, A., Huddleston, J., et al. (2015). An integrated map of structural variation in 2,504 human genomes. *Nature* 526, 75-81. doi: 10.1038/nature15394 Teumer, A., Li, Y., Ghasemi, S., Prins, B. P., Wuttke, M., Hermle, T., et al. (2019). Genomewide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria. Nature Communications 10, 4130. doi: 10.1038/s41467-019-11576-0 Teumer, A., Tin, A., Sorice, R., Gorski, M., Yeo, N. C., Chu, A. Y., et al. (2016). Genomewide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. Diabetes 65, 803-817. doi: 10.2337/db15-1313 Tin, A., and Köttgen, A. (2020). Genome-Wide Association Studies of CKD and Related Traits. Clinical Journal of the American Society of Nephrology, CJN.00020120. doi: 10.2215/CJN.00020120 Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Research 38, e164e164. doi: 10.1093/nar/gkq603 Wuttke, M., Li, Y., Li, M., Sieber, K. B., Feitosa, M. F., Gorski, M., et al. (2019). A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nature Genetics 51, 957-972. doi: 10.1038/s41588-019-0407-x Yang, J., Ferreira, T., Morris, A. P., Medland, S. E., Madden, P. A. F., Heath, A. C., et al. (2012). Conditional and joint multiple-SNP analysis of GWAS summary statistics

909 identifies additional variants influencing complex traits. *Nature Genetics* 44, 369–375. 910 doi: 10.1038/ng.2213 911 Yang, J., Lee, S. H., Goddard, M. E., and Visscher, P. M. (2011). GCTA: a tool for genome-912 wide complex trait analysis. American journal of human genetics 88, 76-82. doi: 913 10.1016/j.ajhg.2010.11.011 914 Zanetti, D., Rao, A., Gustafsson, S., Assimes, T. L., Montgomery, S. B., and Ingelsson, E. (2019). Identification of 22 novel loci associated with urinary biomarkers of albumin, 915 916 sodium, and potassium excretion. Kidney International 95, 1197-1208. doi: 917 10.1016/J.KINT.2018.12.017 918 Zhou, X., and Stephens, M. (2012). Genome-wide efficient mixed-model analysis for 919 association studies. Nature genetics 44, 821–824. doi: 10.1038/ng.2310 920 Zolotarov, Y., Ma, C., González-Recio, I., Hardy, S., Franken, G. A. C., Uetani, N., et al. 921 (2021). ARL15 modulates magnesium homeostasis through N-glycosylation of 922 CNNMs. Cell Mol Life Sci 78, 5427–5445. doi: 10.1007/s00018-021-03832-8 923 924 925

### Studies - Genotyping - GWAS



#### Meta-Analysis Strategy



### Post-GWAS Analysis and Polygenic Scores

